The human papillomavirus vaccine and risk of anaphylaxis

Neal A. Halsey MD

Early release, published at www.cmaj.ca on Sept. 1, 2008.

In this issue of CMAJ, Brotherton and colleagues report a comprehensive investigation revealing higher than expected rates of apparent anaphylaxis following vaccination with the quadrivalent human papillomavirus (HPV) vaccine in Australian children. The cause of these reactions remains somewhat unclear and needs further investigation. Of note, rates of anaphylaxis, if confirmed, may not be as high in other populations. Further investigations may assist in clarifying differences between the Australian study and other reports.

The use of a review panel with broad expertise in vaccines, allergy, immunology and pediatrics by Brotherton and colleagues and their use of the Brighton collaboration definition of anaphylaxis strengthen the evidence that the reactions were indeed anaphylaxis. This also strengthens their conclusions that the rate of anaphylaxis in the Australian population following HPV vaccination was higher than the rates observed following other vaccinations.

Before concluding that the HPV vaccine is associated with higher rates of anaphylaxis than other vaccines everywhere, cases in other populations should be reviewed. In the United States, 15 cases of anaphylaxis or anaphylactoid reactions following HPV vaccination were reported to the Vaccine Adverse Events Reporting System in 2007. As of July 21, 2008, 11 cases have been reported in 2008. Over 13 million doses of this vaccine had been distributed as of the end of 2007. Although there may be underreporting, the rate of about one case per one million vaccinations is consistent with the rate of anaphylaxis following several other vaccines. Regardless of the true rate, the causes of rare serious adverse events should be identified and vaccines made as safe as possible to maximize benefits and maintain public confidence in vaccines and immunization programs.

Differentiating hypersensitivity reactions from fainting and anxiety reactions can be difficult, especially in busy, school-based clinics. The Clinical Immunization Safety Assessment Network, sponsored by the US Centers for Disease Control and Prevention, has developed guidelines and an algorithm to assist clinicians in the assessment of suspected immediate hypersensitivity reactions and decision-making about administering subsequent doses of vaccine.

Anaphylaxis that occurs within minutes of exposure is usually associated with pre-existing IgE antibodies induced by prior exposure to the allergen. Brotherton and colleagues speculate that the reactions observed could have been due to prior sensitization from yeast proteins in the hepatitis B vaccine or HPV antigens from prior infections. However, 5 of the 7 women developed anaphylaxis after the first dose of HPV vaccine and, for 4 of the women, the results of skin tests were negative for yeast, polysorbate 80 stabilizer and the HPV vaccine. Skin testing performed within a few weeks of exposure could result in false negative tests because of the time lag for host reconstitution of IgE antibodies that were consumed in the reaction. The women in the study by Brotherton and colleagues were tested at least 6 weeks after the reactions, which should have been sufficient time for reconstitution. Testing for serum IgE-specific antibodies can sometimes avoid the pain, inconvenience and risks of reactions associated with skin testing. Brotherton and colleagues appropriately performed skin-prick testing followed by intradermal testing with vaccine diluted to 1:10 and 1:100, because testing with undiluted vaccines can result in high rates of nonspecific reactions leading to the false conclusion that a patient has true hypersensitivity to the vaccine.

The authors also note that polysorbate 80 in the vaccine may have caused anaphylactoid reactions. Anaphylactoid reactions are clinically indistinguishable from anaphylaxis, but IgE antibody is not involved and histamine is released through other mechanisms. However, in several cases where polysorbate 80 was determined to be the cause, the patients had positive reactions to the skin-prick test to this product; this was not the case in the study by Brotherton and colleagues. Also, most case reports of anaphylactoid reactions involved receipt of larger doses of polysorbate 80 than the 50 µg present in the HPV vaccine. Further investigations are indicated to identify the true cause of the reactions in Australia.

Specific allergens responsible for causing immediate hypersensitivity reactions have been identified with immunization programs.

Key points

- The causes of apparent anaphylaxis or anaphylactoid reactions among children in Australia following HPV vaccination are unclear.
- The rate of anaphylaxis following HPV vaccination should be confirmed in other populations.
- These rare but serious adverse events highlight the importance of postlicensure vaccine safety studies and careful management in immunization clinics.

From the Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
hypoallergenic and is used for children who have immediate hypersensitivity reactions to gelatin. Of note, a study of patients who had anaphylaxis following a vaccination showed that subsequent doses were usually contraindicated. However, people at high risk of complications from the disease are faced with the difficult decision to proceed with vaccination, some experts recommend using alternative vaccines produced by alternative manufacturers or desensitization under controlled conditions if necessary or both. It would be helpful to know if any of the women in the study by Brotherton and colleagues receive additional doses of any HPV vaccine and if any adverse events occurred.

The HPV vaccine is associated with high rates of fainting in adolescents, which can result in serious head injuries. However, people at high risk of complications from the disease are faced with the difficult decision to proceed with in-depth evaluations and to possibly administer additional doses of vaccine. Is it safe to administer additional doses of HPV vaccine to patients with negative skin-test results to key vaccine components and the vaccine? Although negative skin-test results can be very helpful, such results do not rule out the possibility of serious immediate hypersensitivity reactions following rechallenge in those who have had immediate hypersensitivity reactions. For patients at high risk of complications from the disease, if a decision is made to proceed with vaccination, some experts recommend using alternative vaccines produced by alternative manufacturers or desensitization under controlled conditions if necessary or both. It would be helpful to know if any of the women in the study by Brotherton and colleagues receive additional doses of any HPV vaccine and if any adverse events occurred.

The HPV vaccine is associated with high rates of fainting in adolescents, which can result in serious head injuries. These adverse events emphasize the need for recommendations to keep adolescents and children under close observation (preferably sitting) for at least 15 minutes after vaccination. The risk of rare, but potentially serious, adverse events such as fainting and immediate hypersensitivity reactions following vaccination should not discourage the administration of this vaccine in school-based clinics, which are an effective means of reaching adolescents. Planning for these programs must include preparation to rapidly detect and treat adverse events, including fainting, anxiety and immediate hypersensitivity reactions. Although most such reactions are uncommon or rare, these events can disrupt otherwise well-planned public health programs.

Competing interests: Neal Halsey serves on the data and safety monitoring boards for studies of vaccines sponsored by Merck and for a Harvard investigator conducting a postlicensure safety study of Gardasil in a managed care organization. He has participated in the writing of a manuscript on the immunology of HPV infections sponsored by GlaxoSmithKline, and he has received an honorarium for attending a 1-day meeting during the writing process.

Acknowledgements: I thank Rosanna Setse for technical support and Tina Proveaux for assistance with the preparation of the manuscript.

Funding: This article was supported in part by funding from the Centers for Disease Control and Prevention (CDC), by a grant through an agreement with America’s Health Insurance Plans and CDC (grant number 103019).

REFERENCES
1. Brotherton JML, Gold MS, Kemp AS, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008;179:525-33
2. Centers for Disease Control and Prevention. Gardasil Vaccine Reports to VAERS. Atlanta (GA); The Center; 2008. Available: www.cdc.gov/vaccinesafety/vaers/gardasil.htm (accessed 2008 July 30).
3. Wood RA, Berger M, Dreskin SC, et al. An Algorithm for Management of Patients with Hypersensitivity Reactions Following Vaccines. Pediatrics. In press.
4. Hamilton RG, Aikinson NF Jr. In vitro assays for the diagnosis of IgE-mediated disorders. J Allergy Clin Immunol. 2004;114:213-25.
5. Wood RA, Setse R, Halsey N; For the Clinical Immunization Safety Assessment (CISA) Network Hypersensitivity Working Group. Irritant skin test reactions to common vaccines. J Allergy Clin Immunol 2007;120:478-81.
6. Rusznak C, Peebles RS Jr. Anaphylaxis and anaphylactoid reactions. A guide to prevention, recognition, and emergent treatment. Postgrad Med 2002;111:101-4, 107-8, 111-4.
7. Steele RH, Limaye S, Cleland B, et al. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology (Carlton) 2005;10:317-20.
8. Coors EA, Seybold H, Merk HF, et al. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol 2005;95:593-9.
9. Institute for Vaccine Safety. Allergens. Baltimore (MD): Johns Hopkins Bloomberg School of Public Health; 2008. Available: www.vaccinesafety.edu /components-Allergens.htm (accessed 2008 July 31).
10. Pool V, Braun MM, Kelso IM, et al. VAERS Team. US Vaccine Adverse Event Reporting System. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics. 2003;112:e71.
11. Centers for Disease Control and Prevention. Syncope After Vaccination — United States, January 2005–July 2007. MMWR Morb Mortal Wkly Rep 2008;57:457-60.
12. Kroger AT, Atkinson WL, Marcuse EK, et al.; Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2006;55(RR-15):1-48.

Correspondence to: Dr. Neal A. Halsey, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St., Rm. W5041, Baltimore MD 21205; nhalsey@jhsphs.edu